Activation of plasminogen by urokinase plasminogen activator (uPA) plays important roles in several physiological and pathological conditions. Cells secrete uPA as a single-chain molecule (scuPA). scuPA can be activated by proteolytic cleavage to a two-chain enzyme (tcuPA). scuPA is also activated when it binds to its receptor (uPAR). The mechanism by which the enzymatic activity of the scuPA/suPAR complex is regulated is only partially understood. We now report that the plasminogen activator activity of the scuPA/suPAR complex is inhibited by Glu-and Lys-plasminogen, but not by mini-plasminogen. In contrast, neither Glu-nor Lys-plasminogen inhibits the activation of plasminogen by two-chain uPA. Inhibition of scuPA/suPAR activity was evident at a Glu-plasminogen concentration of approximately 100 nM, and at physiologic plasma concentrations inhibition was nearly complete. A plasminogen fragment containing kringles 1-3 inhibited the enzymatic activity of scuPA/suPAR with a Ki = 1.9 µM, increased the Km of scuPA/suPAR from 18 nM to 49 nM and decreased the Kcat approximately 3-fold from 0.035 to 0.011 sec -1
Introduction
Urokinase type plasminogen activator (uPA) has been implicated in diverse physiological and pathological processes, including cancer invasiveness and metastasis [1] [2] [3] [4] , angiogenesis [5] [6] [7] [8] , inflammation 9 , and fibrinolysis [10] [11] [12] . uPA is synthesized as a single chain molecule (scuPA) that expresses little or essentially no intrinsic [13] [14] [15] plasminogen activator activity. scuPA can be activated by proteolytic cleavage at Leu
158
-Ile 159 to a two-chain enzyme (tcuPA) 16 , or it can be converted to an enzymatically active single-chain molecule by binding to its high affinity cellular receptor (uPAR) [17] [18] [19] .
Mice lacking uPA 20 or uPAR 21, 22 appear to develop normally. Yet, mice lacking uPA are susceptible to lethal pulmonary infection by cryptococcus neoformans, an observation that has been attributed to impaired recruitment of inflammatory cells into the lung 9, 23, 24 , and peritoneal macrophages from homozygous uPAR -/-mice display impaired cell-associated plasminogen activator activity 21 . Fibrin clots typically contain neutrophils and macrophages that express uPAR and accelerate uPA-mediated clot lysis. In accordance with this, lysis of fibrin clots by macrophages from patients with paroxysmal nocturnal hemoglobinuria, who are predisposed to thrombosis and whose leukocytes lack cell surface uPAR, is impaired compared with cells from normal individuals 25 .
These studies suggest that the binding of scuPA to uPAR is involved in clot lysis at plasma concentrations of reactants and that regulation of uPA/uPAR may play an important role in the pathogenesis of certain disease states.
Our previous studies showed that the scuPA/suPAR complex is a potent plasminogen activator with a capacity to lyse plasma clots that exceeds either scuPA or in vitro and in vivo 19 . However, unlike tcuPA, which is rapidly and essentially irreversible inactivated by plasminogen activator type I (PAI-1), the inactivation of scuPA bound to soluble uPAR (suPAR) by PAI-1 is slow and reversible 26 . Activation and inactivation of scuPA/suPAR also depends on the amino acid composition of the synthetic substrate used to detect the activity of the plasmin that is generated. Specifically, the activity of scuPA/suPAR is regulated by the plasmin substrate H-D-norleucyl-hexahydrotyrosyl-lysine-pnitroanilide diacetate (*L*YK-P) but not by H-D-valyl-L-leucyl-L-lysine-pnitroanilide diacetate (D-VLK-p) 27, 28 .
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To date, the mechanism by which the activity of cell-associated uPA is constrained has not been fully elucidated. In the present paper we report that the plasminogen activator activity of the scuPA/suPAR complex is inhibited by physiological concentrations of Glu-plasminogen.
This inhibition by Gluplasminogen is abolished by fibrin. These studies provide insight into the regulation of cell associated uPA-mediated plasminogen activation and identify a novel mechanism underlying its fibrin specificity.
Materials and Methods

Materials.
Single chain urokinase (scuPA) and recombinant soluble urokinase receptor (suPAR) were purified, characterized, and radiolabeled as previously reported 29, 30 . Glu-plasminogen, Lys-plasminogen and miniplasminogen, and the plasmin substrate Spectrazyme-PL were kindly provided by American Diagnostica (Greenwich, CT).
Lyophilized human fibrinogen depleted of plasminogen and thrombin and human -thrombin were obtained from Sigma (St Louis, MO). A was resistant to proteolysis by uPA as confirmed by SDS-PAGE.
Plasminogen activator activity. Plasminogen activator activity was determined by adding scuPA (5 nM) and an equimolar concentration of suPAR, or 5 nM tcuPA to a reaction mixture containing various concentrations of Glu-, Lys-or mini-plasminogen and the plasmin chromogenic substrate Spectrazyme PL (500 µM) in phosphate buffered saline (PBS) at 37 o C and the light absorbance at 405 nm was measured continuously over time. The initial velocities of plasmin generation at different concentrations of plasminogen were calculated from the change in the A 405 nm over time. The initial velocity of the reaction at each plasminogen concentration was obtained by calculating the change in the rate of A 405 over different time intervals and the results were expressed as the change in optical density ( OD)/min which represents the slope of the initial velocity of plasminogen activation. To measure changes in the Km and Vmax of plasmin generation, the rates of change in OD were compared to a standard curve made with known concentrations of plasmin, as described 18, 31 , and the results were calculated using a double reciprocal plot. In another set of experiments, a fixed concentration of Glu-plasminogen (20 nM) was added to suPAR (5 nM) and scuPA (5 nM) in the presence of various concentrations of plasminogen fragments and the plasminogen activator activity was measured as above. In a third set of experiments, the capacity of various concentrations of kringles 1-3 to inhibit this reaction was calculated using a Dixon plot.
Plasminogen activation on cell surfaces.
Monolayers of cultured human umbilical vein endothelial cells (HUVEC) were prepared as described 32 . The cells were incubated in glycine buffer pH 3.0 for 5 min to remove endogenous uPA from cellular uPAR and then washed 3 times with PBS, pH 7.4. The cells were then incubated in PBS containing 15 nM Gluplasminogen, 50 µM Spectrazyme PL, 5 nM scuPA or 5 nM tcuPA alone, or either uPA in the presence of 1.5 µM K1-3 for 30 min, the buffer was removed, and the OD at 405 nm was measured. 19, 33 was resuspended to a specific activity of 60,000 cpm/mL in PBS containing 3 mg/mL fibrinogen and increasing concentrations of Glu-plasminogen or in plasminogen-free plasma repleted with plasminogen in the same way. In other experiments, plasminogen was added at a fixed concentration of 1 µM. Clots were formed by placing 0.4 mL soluble fibrinogen or plasma in 16-mm diameter tissue culture wells (Corning, Corning NY) before adding thrombin (0.2 or 0.4 U/mL final concentration, respectively). Fibrinolysis was measured as described 19 . Briefly, radiolabeled fibrin or plasma clots were overlaid with serum or PBS containing 25 nM scuPA/suPAR complex or 25 µL murine plasma (see below) for two hr at 37°C, and radiolabeled soluble fibrin degradation products released into the overlying fluids were measured. Fibrinogen concentration. Mice were injected with the specified amounts of scuPA or scuPA/suPAR. Two hrs later, blood was drawn by cardiac puncture into sodium citrate (0.32% final concentration) and aprotinin (1 mg/mL final concentration). Plasma was prepared by centrifugation at 5000 rpm. Thrombin
Binding of Plasminogen
(1 U/mL) was added and the time to form a visible clot was measured. The concentration of fibrinogen in the plasma was determined by reference to the thrombin time measured in parallel using purified fibrinogen. In another set of experiments,
125
I-fibrinogen resuspended in 0.5 mL saline supplemented with unlabeled fibrinogen (50,000 cpm/µL) was injected IV into mice immediately before injecting scuPA or scuPA/suPAR (11.3 mg/mL). Two hr later, blood was
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Binding of scuPA/suPAR to fibrin. scuPA and tPA were radiolabled to a specific activity of 380,000 cpm/mL 32 and used at a final concentration of 100 nM.
Binding of scuPA/suPAR to fibrin was determined as described 34 . Briefly, Proteolysis of radiolabeled globin and fibrinogen. Fibrinogen was iodinated as described above. containing anti-uPAR IgG for 2 hr at 4°C and 0.3 mL protein G-Agarose was added for an additional 2 hr. The beads were centrifuged at 5,000 rpm for 10 min and the supernatant was decanted. The precipitate was washed three times with RIPA buffer 36, 37 and the radioactivity was measured.
Results
Fibrin specificity of the scuPA/suPAR complex
We have previously reported that the complex between scuPA and suPAR is a potent plasminogen activator and that its fibrinolytic activity exceeds that of scuPA alone, both in-vitro 19 and in-vivo 12 . Whether this activity is specific for fibrin, and if this is the case, the mechanism underlying this fibrin specificity, has not been established.
To address these issues, we first compared the consumption of plasma fibrinogen in vivo in mice injected with scuPA, to that in animals given an equal amount of scuPA as preformed scuPA/suPAR complexes. ScuPA was injected at concentrations that lyse plasma clots 19, 12 .
Mice were injected intravenously with scuPA/suPAR in doses ranging from 0.1-11.3 mg/kg (~4.4 µM estimated maximal initial plasma concentration) and the concentration of fibrinogen in plasma was measured two hours later. Even at the highest concentrations injected, scuPA/suPAR had no effect on the plasma concentration of fibrinogen ( Figure 1A ). In contrast, the same amount of injected scuPA decreased the plasma concentration of fibrinogen by more than 50% ( Figure 1B ).
As a second approach, mice were injected with Experiments were then performed to determine whether the fibrinolytic activity of scuPA/suPAR is due to the proteolytic conversion of scuPA to tcuPA either while still bound to the receptor or after its elution. To examine this question, mice were injected with either tcuPA or tcuPA/suPAR at the same concentrations shown in Figure 1 . As expected, both tcuPA and tcuPA/suPAR caused a greater reduction in plasma fibrinogen than scuPA or scuPA/suPAR, decreasing the circulating concentrations of fibrinogen from 263±42 to 53±21 and 76±34 mg/dL, respectively. In contrast, scuPA/suPAR, had no effect on the plasma fibrinogen concentration (see Figure 1 ).
Taken together, these data strongly suggest that the fibrinolytic activity is initiated by a complex between scuPA and suPAR. To test this assumption directly, mice were injected with complexes prepared with 125 I-scuPA/suPAR.
Three minutes later, consistent with its t 1/2 in plasma 12 , blood samples were taken, plasma was prepared, and the complexes were immunoprecipitated with anti-uPAR antibodies 37 . Anti-uPAR precipitated 125 I-scuPA only when it was injected together with suPAR, consistent with preservation of the complex ( Figure   2C ). The same results were obtained when the experiment was performed in the presence of 2 µM Glu-plasminogen in saline (data not shown) indicating that plasminogen does not disrupt complex formation in this setting.
To examine the mechanism underlying the fibrin specificity of the scuPA/suPAR complex in greater detail, we compared its plasminogen activator activity using radiolabeled fibrin and globin as substrates. scuPA/suPAR (25 nM) did not lyse clots prepared from purified fibrinogen. However, lysis was readily observed when serum was present ( Figure 3A) , consistent with our previous observations 19 . In contrast, scuPA/suPAR (25 nM) caused minimal proteolysis of radiolabeled globin either by itself or in the presence of serum ( Figure 3A ), indicating that serum does not induce scuPA/suPAR plasminogen activator activity. In contrast to scuPA/suPAR, tcuPA caused significant cleavage of both substrates in the absence of serum and addition of serum inhibited tcuPAmediated clot lysis ( Figure 3B ). This indicates that the inability of scuPA/suPAR to induce the proteolysis of globin is not due to the inability of plasmin to proteolyse this substrate. These latter results both affirm the fibrin specificity of the complex and indicate that fibrin alone is not sufficient for scuPA/suPAR to express plasminogen activator activity. In support of this, we did not detect binding of scuPA/suPAR to fibrin clots, in contrast to the binding observed with tPA ( Figure 4) .
Regulation of scuPA/suPAR plasminogen activator activity by plasminogen
To pursue the implications of the fibrin-and serum-dependence of scuPA/suPAR-mediated fibrinolysis, we took two findings into account. First, scuPA binds to plasminogen 38 . Second, the data of Scully et al. strongly
suggests that scuPA interacts with the kringles of plasmin 39 . Therefore, we next examined the effect of plasminogen on the plasminogen activator activity of the scuPA/suPAR complex.
The data presented in Figure 5 show the effect of increasing concentrations of Glu-plasminogen on plasminogen activator activity mediated by scuPA/suPAR. A dose-dependent increase in plasmin formation was measured at concentrations of plasminogen up to 80 nM, as expected. However, at concentrations above 160 nM, a dose-dependent inhibition of plasmin formation was observed. At near physiological plasma concentrations (1.44 µM), inhibition of PA activity was almost complete; i.e. the activity was only 4% of that seen at optimal (80 nM) concentrations of plasminogen.
Glu-plasminogen, the predominant form of plasminogen in plasma, assumes a predominantly closed structure 40 . Cleavage of Glu-plasminogen by plasmin liberates its N-terminal 77 amino acids and thereby causes the molecule, designated Lys-plasminogen, to assume a more open conformation, that renders it more susceptible to activation by uPA 41 . Therefore, we next examined the effect of releasing this N-terminal fragment on the capacity of plasminogen to regulate its subsequent activation by scuPA/suPAR. Lys-plasminogen exerts a biphasic effect on scuPA/suPAR-mediated plasminogen activation, similar to that seen with Glu-plasminogen ( Figure 5 ). Maximal activity was seen at a Lysplasminogen concentration of 160 nM, while the activity of scuPA/suPAR was inhibited at higher concentrations. However, Lys-plasminogen was a less potent inhibitor of scuPA/suPAR ( Figure 5 ). Even at the highest concentration tested (1.44 µM), inhibition of suPAR/scuPA by Lys-plasminogen was only approximately 65% of that seen at optimal substrate concentrations (160 nM).
This stands in contrast to the near total inhibition seen at the same concentrations of Glu-plasminogen.
Lys-plasminogen is composed of five kringle structures and the protease
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. Several experiments were performed to delineate their involvement in the regulation of scuPA/suPAR. First, we examined the activity of scuPA/suPAR in the presence of mini-plasminogen, which lacks the kringles 1-4. Miniplasminogen, like Glu-and Lys-plasminogen, induced a dose-dependent increase in scuPA/suPAR-mediated plasmin formation ( Figure 5 ). In contrast, mini-plasminogen did not inhibit scuPA/suPAR activity, even at concentrations as high as 1400 nM.
The observation that above certain concentrations both Glu-and Lysplasminogen inhibit scuPA/suPAR, indicates that amino acids 1-77 are not essential for this effect.
The fact that mini-plasminogen did not inhibit suPAR/scuPA under the same conditions suggests that the negative regulatory element is situated within a plasminogen fragment that begins at amino acid 78
and includes kringles 1-4. Therefore, we next examined the effect of kringles 1-3, a plasminogen fragment that has been described to have anti-angiogenic activity 43, 44 , on plasminogen activation by scuPA/suPAR complex. Plasminogen 
Activation of fibrinolysis by scuPA/suPAR
The observation that plasminogen inhibits the activity of scuPA/suPAR at sub-physiological plasma concentrations fails to explain how the complex could activate plasminogen under patho-physiological conditions. To address this question we first depleted plasma of plasminogen. Plasminogen-free plasma was then repleted with radiolabeled fibrinogen and varying amounts of exogenous plasminogen. Clots were then formed as in 19 and their cleavage by scuPA/suPAR was measured. Plasminogen lost its capacity to inhibit the activity of scuPA/suPAR in the presence of plasma clots ( Figure 9 ).
In view of this observation and the finding that fibrin is needed to detect the fibrinolytic activity of scuPA/suPAR ( Figure 3A) , we asked if fibrin was able to restore the plasminogen activation activity of the complex in the presence of plasminogen. In accordance with this concept, plasminogen did not inhibit scuPA/suPAR-mediated fibrinolysis in the presence of clots prepared from fibrinogen ( Figure 10 ). Moreover, plasminogen inhibited scuPA/suPARmediated, plasmin-dependent lysis of 14 C-globin ( Figure 11A ), as well as lysis of 125 I-fibrinogen ( Figure 11B ).
Fibrin and 6-AHA both bind to lysine binding sites in plasminogen 41 and 6-AHA inhibits the binding of plasminogen to scuPA/suPAR (Figure 8 ).
Consequently, we asked whether 6-AHA would recapitulate the capacity of fibrin to restore the inhibitory activity of plasminogen on scuPA/suPAR. Indeed, the inhibitory activity of plasminogen was not expressed in the presence of 1 µM 6-AHA ( Figure 12 ). 
Regulation of cell-associated uPA plasminogen activator activity
Lastly, we asked if our findings hold true in the physiological context of cell-associated plasminogen activation. Therefore, we examined the effect of K1-3 on the cell-associated plasminogen activator activity of scuPA using HUVEC as the source of uPAR. Cells were pretreated with glycine buffer, pH 3, to elute endogenous uPA. Five nM scuPA or tcuPA was added alone or in the presence of K1-3 (1.5 µM), followed by 15 nM plasminogen and the plasmin chromogenic substrate. K1-3 inhibited the activation of plasminogen to plasmin when scuPA was added, but did not affect the plasminogen activator activity of tcuPA ( Figure 13 ).
Discussion
We have previously reported that the complex between scuPA and uPAR, or its soluble counterpart suPAR, expresses plasminogen activator activity, but the complex has kinetic properties 18 and is regulated 26,27 in a manner that differs from that of tcuPA and tPA. In the present paper, we report that the scuPA/suPAR complex, unlike scuPA or tcuPA, did not deplete plasma fibrinogen in mice at a concentration 45-fold higher than was shown previously to express fibrinolytic activity in vivo 12 .
The mechanism underlying the fibrin specificity of scuPA/suPAR complex differs from that previously reported for other plasminogen activators. Our findings indicate that the catalytic activity of the scuPA/suPAR complex is inhibited by physiological concentrations of its substrate plasminogen. The inhibitory activity resides in a plasminogen fragments composed of kringles 1-3.
The inhibitory effect of plasminogen was completely abolished by fibrin but not by other plasma components, including fibrinogen. Kringles 1-3 also inhibited endothelial cell-associated scuPA-mediated plasminogen activation.
Based on our findings, we postulate that the activity of scuPA/suPAR is restrained in plasma by plasminogen in the absence of fibrin clots. Fibrin reverses this inhibition, allowing fibrinolysis to proceed. Once substantial clot lysis has occurred, plasminogen-mediated inhibition is restored.
The mechanism that we propose to explain the fibrin specificity of the scuPA/suPAR complex is supported by the fact that 6-AHA both inhibits binding of the complex to plasminogen and abolishes its capacity to inhibit the plasminogen activator activity, suggesting that both are kringle mediated. The fact that the binding of plasminogen to fibrin is also kringle mediated 41 helps to explain the capacity of fibrin to overcome the inhibitory effect of plasminogen. It appears likely that plasminogen bound to fibrin through its kringles loses its capacity to bind to scuPA/suPAR and thereby its inhibitory effect on the complex.
In addition, it is possible to postulate that plasminogen bound to fibrin is a preferred substrate for the scuPA/suPAR bound to plasminogen.
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This suggests that two sub-populations of plasminogen exist in the presence of fibrin clots. Soluble plasminogen retains its capacity to inhibit scuPA/suPAR, while clot-bound plasminogen does not. In this way, the activity of scuPA/suPAR is confined to the area of bound plasminogen, i.e. on the clot surface. Taking in consideration that the plasminogen fragment containing kringles 1-3 regulates cell-associated plasminogen activation by scuPA bound to uPAR as well, our data provide new insights into the regulation of cell-and clotassociated plasminogen activation in plasma and demonstrate a novel mechanism for its fibrin specificity.
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